Medicine, public health, and wellness.
(MedPage Today) -- PHOENIX -- An investigational pan-amyloid binding tracer proved its mettle in detecting and quantifying cardiac amyloidosis, particularly among early, low-burden cases, in a phase III study. In the REVEAL study, the positron...
Also in Health
More Health Stories
(MedPage Today) -- Microvascular hemodynamics might provide an early marker of poor recovery despite successful large-vessel thrombectomy in acute ischemic stroke, an imaging study suggested. Poor capillary bed perfusion as indicated by relative...
(MedPage Today) -- Note that some links may require registration or subscription. Pope Leo XIV announced he will undergo surgery "in the coming days" to remove a nodule on his lung, in the first major health event of his 17-month pontificate...
(MedPage Today) -- "The public should not be subject to these quack medicines." -- Jeffrey Klausner, MD, MPH, of Herpes Cure Advocacy, responding to news that FDA warned Amazon for selling unapproved herpes treatments. "The response has been...
(MedPage Today) -- PHOENIX -- The development of a PDE9 inhibitor for heart failure hit a major roadblock, as two phase II placebo-controlled trials were suspected of having tested the wrong dose. In both heart failure with reduced ejection...
Just 40 percent of Americans reported a lot of confidence in U.S. hospitals and health clinics, the same proportion as in Portugal and Uruguay.
Steven Quay, a biopharmaceutical executive with no background in infectious diseases, is no longer being considered for director of the National Institute for Allergy and Infectious Diseases.
The AHA is once again suing the Trump administration over its plan to revamp a federal drug discount program into one that provides after-the-fact rebates instead of upfront discounts.
The federal government has released new quality ratings for Medicare Advantage insurers for 2027, with Humana emerging as the biggest winner. But deep uncertainty remains around Medicare Advantage quality measures,…
Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The Trump administration wants to make three big changes to the U.S. Census, including eliminating questions about race, ethnicity, and sexual orientation and excluding anyone who is not a citizen…
The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.
As the midterm elections draw near, the MAHA movement is nearly invisible on the campaign trail and struggling to find a financial or messaging foothold in key races.
